[{"address1": "3 Sugar Creek Center Boulevard", "address2": "Suite 525", "city": "Sugar Land", "state": "TX", "zip": "77478", "country": "United States", "phone": "713 489 8654", "website": "https://tvarditherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.", "fullTimeEmployees": 11, "companyOfficers": [{"maxAge": 1, "name": "Dr. Imran  Alibhai Ph.D.", "age": 48, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 857330, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wallace  Hall", "age": 62, "title": "Founder, President & Director", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Conn J.D., M.B.A.", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 552595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Kauh M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 565830, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Tweardy M.D.", "title": "Co-Founder & Scientific Advisory Board Member", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald A. DePinho M.D.", "age": 69, "title": "Co-Founder & Chairman of Scientific Advisory Board", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael T. Lewis Ph.D.", "title": "Co-Founder & Scientific Advisory Board Member", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  Larson DABT, Ph.D.", "age": 62, "title": "Senior Vice President of R&D", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  O'Brien CPA", "title": "VP of Finance & Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yixin  Chen Ph.D.", "age": 63, "title": "Vice President of CMC", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 5.16, "open": 5.16, "dayLow": 4.9, "dayHigh": 5.16, "regularMarketPreviousClose": 5.16, "regularMarketOpen": 5.16, "regularMarketDayLow": 4.9, "regularMarketDayHigh": 5.16, "payoutRatio": 0.0, "volume": 257280, "regularMarketVolume": 257280, "averageVolume": 232932, "averageVolume10days": 1266780, "averageDailyVolume10Day": 1266780, "bid": 4.79, "ask": 5.16, "bidSize": 1, "askSize": 1, "marketCap": 46605840, "fiftyTwoWeekLow": 4.9, "fiftyTwoWeekHigh": 43.65, "allTimeHigh": 1067.292, "allTimeLow": 4.9, "fiftyDayAverage": 28.2635, "twoHundredDayAverage": 22.563715, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5865842, "forwardPE": -1.961326, "profitMargins": 0.0, "floatShares": 6106115, "sharesOutstanding": 9377433, "sharesShort": 1175876, "sharesShortPriorMonth": 675167, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.1254, "heldPercentInsiders": 0.43151, "heldPercentInstitutions": 0.2078, "shortRatio": 2.57, "impliedSharesOutstanding": 9735926, "bookValue": 3.513, "priceToBook": 1.4147452, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -23632000, "trailingEps": -2.25, "lastSplitFactor": "1:3", "lastSplitDate": 1744761600, "enterpriseToEbitda": -0.198, "52WeekChange": -0.4886831, "SandP52WeekChange": 0.16625166, "quoteType": "EQUITY", "currentPrice": 4.97, "targetHighPrice": 46.0, "targetLowPrice": 4.0, "targetMeanPrice": 14.33333, "targetMedianPrice": 8.0, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 40994000, "totalCashPerShare": 4.372, "ebitda": -29606000, "totalDebt": 254000, "quickRatio": 3.839, "currentRatio": 4.039, "debtToEquity": 0.771, "operatingCashflow": -25045000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "TVRD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NCM", "messageBoardId": "finmb_570288312", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1761350309, "regularMarketTime": 1761336000, "shortName": "Tvardi Therapeutics, Inc.", "longName": "Tvardi Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391178600000, "epsTrailingTwelveMonths": -2.25, "epsCurrentYear": -2.228, "priceEpsCurrentYear": -2.2307003, "fiftyDayAverageChange": -23.2935, "fiftyDayAverageChangePercent": -0.82415485, "twoHundredDayAverageChange": -17.593716, "twoHundredDayAverageChangePercent": -0.7797349, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "marketState": "CLOSED", "postMarketChangePercent": 0.641859, "postMarketPrice": 5.0019, "postMarketChange": 0.0319004, "regularMarketChange": -0.19, "regularMarketDayRange": "4.9 - 5.16", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 232932, "fiftyTwoWeekLowChange": 0.069999695, "fiftyTwoWeekLowChangePercent": 0.014285652, "fiftyTwoWeekRange": "4.9 - 43.65", "fiftyTwoWeekHighChange": -38.68, "fiftyTwoWeekHighChangePercent": -0.88613975, "fiftyTwoWeekChangePercent": -48.86831, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "isEarningsDateEstimate": true, "regularMarketChangePercent": -3.68217, "regularMarketPrice": 4.97, "displayName": "Tvardi Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]